Figure 2From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results Progression-free (PFS) and overall survival (OS) according to age. (A) PFS according to Age (<70 and ≥70 years); (B) PFS according to Age (<75 and ≥75 years); (C) OS according to Age (<70 and ≥70 years); (D) OS according to Age (<75 and ≥75 years). OS: overall survival, PFS: progression-free survival.Back to article page